CanSino Biologics Inc
06185
Company Profile
Business description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHNT: +86 4009222099
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,105
Stocks News & Analysis
stocks
AMD earnings: Data center demand still looks quite strong to us
AMD has the components to target $100 billion of AI revenue in the next few years.
stocks
PayPal earnings: Growth slows, new CEO appointed
We expect to lower our fair value estimate of PayPal stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,187.30 | 6.40 | 0.07% |
| CAC 40 | 8,262.16 | 82.66 | 1.01% |
| DAX 40 | 24,603.04 | 177.75 | -0.72% |
| Dow JONES (US) | 49,501.30 | 260.31 | 0.53% |
| FTSE 100 | 10,402.34 | 87.75 | 0.85% |
| HKSE | 26,847.32 | 12.55 | 0.05% |
| NASDAQ | 22,904.58 | 350.61 | -1.51% |
| Nikkei 225 | 54,293.36 | 427.30 | -0.78% |
| NZX 50 Index | 13,470.76 | 3.47 | 0.03% |
| S&P 500 | 6,882.72 | 35.09 | -0.51% |
| S&P/ASX 200 | 8,914.00 | 10.00 | 0.11% |
| SSE Composite Index | 4,102.20 | 34.46 | 0.85% |